ArticleMolecular oncology2022
Integrative analysis of gut microbiome and host transcriptomes reveals associations between treatment outcomes and immunotherapy-induced colitis.
Article in Molecular oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.
- Predicting cancer immunotherapy response from gut microbiomes using machine learning models.Oncotarget · 2022Pooled it
- The lethal symbiont: exploring the pathophysiology of cancer.Physiological reviews · 2026Review
- Omics-based biomarkers of immune-related organ toxicities associated with immune checkpoint inhibitors: a scoping review and evidence map.Frontiers in immunology · 2026Article
- Complete remission in PD-L1 high expression advanced gastric cancer patient with PD-L1 immunotherapy and chemotherapy integration treatment strategy: a case report.Frontiers in oncology · 2025Article
- A machine learning-based method for feature reduction of methylation data for the classification of cancer tissue origin.International journal of clinical oncology · 2024Article
- Mutations Associated With High-Grade irAEs in NSCLC Patients Receiving Immunotherapies.Clinical lung cancer · 2024Article
- Biomarkers associated with immune-related adverse events induced by immune checkpoint inhibitors.World journal of clinical oncology · 2024Review
- Uncovering the flip side of immune checkpoint inhibitors: a comprehensive review of immune-related adverse events and predictive biomarkers.International journal of biological sciences · 2024Review
- Statistical normalization methods in microbiome data with application to microbiome cancer research.Gut microbes · 2023Review
- [Advances in Predictive Research of Immune Checkpoint Inhibitors-related Adverse Events].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2023Article
- Mirroring UC care pathways in refractory immune checkpoint inhibitor (ICI)-mediated colitis: distinct features and common pathways.Clinical journal of gastroenterology · 2023Article
- Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management.International journal of molecular sciences · 2023Review
- Review
- Checkpoint Inhibitor-Induced Colitis: An Update.Biomedicines · 2023Review
- Review
- Modulation of gut microbiota: a novel approach to enhancing the effects of immune checkpoint inhibitors.Therapeutic advances in medical oncology · 2023Review
- Review
- Pharmacological Treatments Available for Immune-Checkpoint-Inhibitor-Induced Colitis.Biomedicines · 2022Review
- Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers.Cancers · 2022Review
- Immune-related adverse events and the balancing act of immunotherapy.Nature communications · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) are widely used to treat various malignancies. Although the gut microbiome is known to influence the efficacy of ICIs on epithelial tumors, the functional interactions between gut taxa and colonic mucosa remain poorly understood. Here we performed transcriptomic profiling and 16S rRNA sequencing to investigate the relationships between mucosal gene expression and microbial composition with ICI responses and gastrointestinal immune-related adverse events (GI irAEs). In responders, genes related to DNA repair and cell cycle signatures were enriched in responders whereas signatures related to innate immune response, NFAT and IFN-γ signaling pathways were enriched in nonresponders. Gut microbial composition revealed an association between moderate GI irAE and favorable response to ICI therapy. Favorable therapeutic responses to ICI and GI irAE treatments were associated with taxa classified as Enterobacteriaceae and were related to ribonucleoprotein complex biogenesis, cytokine-mediated signaling pathway, tRNA metabolic process, and ribonucleoprotein complex assembly in the colon. These findings open new perspectives for improving the efficacy and safety of cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.